Group announces inaugural meeting and charter to promote the use of GenAI in life sciences research and development
ArisGlobal , a leading innovative life sciences technology company and inventor of LifeSphere®, announced the formal constitution of the new GenAI Council, which will meet for the first time this month.
The Global Council is a small and exclusive top group of AI technologists, academics, regulatory leaders and the life sciences (pharmaceutical) industry, including Microsoft. The group is tasked with identifying and presenting repeatable use cases that will inform the targeted deployment of next-generation artificial intelligence and machine learning (AI/ML) innovations, particularly in the form of GenAI.
The main objectives of the Generative AI for Life Sciences Council set out in the Charter include:
- Developing a framework : Creating a comprehensive and adaptable framework that will facilitate the seamless integration of generative AI into life sciences, ensuring its scalability and speed.
- A patient-centered focus : Developing strategies that consistently prioritize patients’ well-being with the goal of improving their experiences and healthcare outcomes through generative AI applications.
- Regulatory compliance : Implementing rigorous mechanisms to ensure full compliance with industry regulations and standards to ensure that all generative AI initiatives comply with legal and ethical requirements.
- Responsible AI practices : Promoting responsible AI practices in the life sciences sector with a focus on transparency, privacy, security, fairness and inclusivity in the development and deployment of AI technologies.
- Exploring, evaluating and promoting use cases for generative AI : continually assessing and supporting various use cases for generative AI in life sciences, driving innovation and identifying opportunities to use AI for better outcomes.
A maximum of 12 companies, appointed by invitation only, will be allocated a place for two senior representatives each to attend the Council’s in-person meetings. The retreat offers members a unique opportunity to freely exchange ideas about their latest ambitions and developments and to learn first-hand from the experiences and ideas of their senior colleagues.
Also Read: DIA, Tufts CSDD Collaborate to Examine the Current Use and Experience with AI in Drug Development
The Council will meet quarterly in rotating global locations. The inaugural meeting in February will be held in Princeton, New Jersey .
Aman Wasan , Managing Director of ArisGlobal, said: “ The launch of the GenAI Council is part of our strategic focus on innovation. We have formed a dedicated innovation group with the clear goal of identifying valuable domain-specific use cases suitable for GenAI and bringing the technology to life as part of the LifeSphere platform so that customers can leverage the advanced technology as part of our SaaS offerings . ”
Elizabeth Smalley , VP of Data & Analytics at ArisGlobal, said: “GenAI and the use of Large Language Models to transform the query and use of diverse bodies of knowledge offers enormous potential to transform life sciences R&D processes in a very positive way change – for the direct benefit of patients and the entire healthcare system. The challenge is to harness that potential in specific, groundbreaking ways to achieve results and show the world what is possible.”
“Generative AI technology is developing at an incredible pace and the new Council for Generative AI in Life Sciences will now look to maximize and advance this potential. Life sciences leaders must proactively adopt and manage the application of these technologies to realize their significant benefits while maintaining a commitment to patient centricity, regulatory compliance and responsible AI standards, and the Council’s mission is to do all of this enable and ensure.”
SOURCE: PRNewswire
